Founded in 2012, the UT Horizon Fund is the strategic fund of the University of Texas System.  Based on cutting edge research at UT System institutions, the UT Horizon Fund works with entrepreneurs and the investment community to help translate innovations out of UT to practical use.   The UT Horizon Fund is evergreen where returns are re-invested for future growth and development.

UT Horizon Fund

DECLATEX

GE Healthcare provides medical technology, intelligent devices, and care solutions. They offer medical imaging, information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies. GE Healthcare's mission is to improve patient care and outcomes by providing innovative healthcare solutions. Their technologies are used in hospitals, clinics, research institutions, and pharmaceutical companies worldwide to diagnose and treat various medical conditions.

GE Healthcare

Decisio Health

Decisio Health is a helping care providers reach accurate decisions quickly and easily.The company's platform focuses on the availability of vital patient data, unprecedented automation, and premier analytics by aggregating disparate data to transparently close the gaps, offering organizations to have an opportunity to identify and correct areas of operational deficiencies, enabling clinicians to monitor patients on a single screen easily accessible from compatible web browsers.

<div>Decisio Health is a technology service provider that facilitates remote patient monitoring and clinical monitoring support services. Its OpticsIQ solution helps clinicians enable remote patient monitoring and virtual consultations, consolidates and prioritizes real-time patient-related data from any device, and helps with identifying at-risk patients through its inbuilt analytics system. The platform, which is an FDA 510(k) Class II cleared medical device, can be focused on a single area of care or scaled across the entire health system.</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Decisio Health is a Houston-based digital health company that offers a clinical decision support platform designed to aggregate and prioritize real-time patient data from various sources and present it visually in a single place. Their flagship product, InsightIQ, utilizes continuous smart bedside monitoring to enable clinical teams to efficiently identify at-risk patients and comply with established clinical guidelines. InsightIQ improves patient outcomes, optimizes workflow, increases collaboration, reduces length of stay, and alleviates "click fatigue."

Houston health tech company raises $18.5M, appoints new leadership

DECISIO® Gains Key Patent for Unique Clinical Dashboard

DECISIO® Health selected for the Houston Business Journal's Innovation Awards

Clinical Surveillance Software and Remote Patient Monitoring

InsightIQ a Remote Patient Monitoring System

smart patient monitoring

Medhealth Outlook

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Houston medtech startup Decisio Health is partnering with GE Healthcare to accelerate a broader deployment of its critical care dashboard.

<div>
 
 Decisio Health is a technology service provider that facilitates remote patient monitoring and clinical monitoring support services. Its OpticsIQ solution helps clinicians enable remote patient monitoring and virtual consultations, consolidates and prioritizes real-time patient-related data from any device, and helps with identifying at-risk patients through its inbuilt analytics system. The platform, which is an FDA 510(k) Class II cleared medical device, can be focused on a single area of care or scaled across the entire health system. 
 
 
 The Texas-based company operates on a B2B basis, where it offers its solutions to healthcare providers and large hospital systems in the US. Decisio offers remote care providers access to real-time patient information from multiple sources, and combines this with the hospital&rsquo;s parameters and protocols. This information is used to support clinical decisions. 
 
 
 In March 2022, the company raised USD 18.5 million in a Series B funding round. The raised funds are to be used for commercialization, improving its platform and growing operations. This brings the total funds raised by the company to USD 31.5 million.
 
</div>

<div>
 
 Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
 
 
 In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
 
 
 
</div>

Nice Healthcare

Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications.Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.

Amicomed

Winston is a men’s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients.The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.

Winston

<div>
 
 Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
 
 
 The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care, wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
 
 
 Key Customers and partnerships
 
 
 Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
 
 
 Fundings and financials
 
 
 As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
 
 
 In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
 an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
 
 Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
 <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
 acquired by financial services company Sun Life Financial
 </a>
 for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
 
 
 
</div>

Dialogue

Grin offers telemedicine and remote monitoring services for orthodontic needs such as braces and teeth straightening. Patients can conduct self-scans (using a Grin device made available to patients in collaboration with 3M) which can be connected to their smartphones and share the feed with orthodontists to access dental solutions. The company plans to go to a subscription-based model after the pandemic. The app also encourages patients to have a 40-second check monthly and share the scan with a dentist in order to allow patients to regularly maintain their dental hygiene.Grin is the only Telehealth disruptor covered on the hub that provides virtual orthopaedic consultations.Funding and financialsIn April 2021, the New York-based teledental platform concluded a seed funding of USD 14 million, and the funds will be allocated to develop additional functionalities by building out its technology. The proceeds will also be used to scale up its team, expand its geographic footprint, and add doctors to the company’s orthodontic partner network.

Grin

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates. 


A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists. 


A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

Decisio Health is a Houston-based digital health company that offers a clinical decision support platform designed to aggregate and prioritize real-time patient data from various sources and present it visually in a single place. Their flagship product, InsightIQ, utilizes continuous smart bedside monitoring to enable clinical teams to efficiently identify at-risk patients and comply with established clinical guidelines. InsightIQ improves patient outcomes, optimizes workflow, increases collaboration, reduces length of stay, and alleviates "click fatigue."
InsightIQ is a decision support device that aggregates, displays, and manages physiological and other patient information generated by third-party medical devices and patient information systems. The software performs automated calculations on patient data collected by third-party devices based on approved clinical protocols at patient care facilities. It is designed to display patient information, facility-specific care protocols, and visual cues to care providers on a single display device, receiving data through the facility's Electronic Medical Record system.
In March 2022, Decisio Health appointed Major General Elder Granger to its board of directors to leverage his expertise in the healthcare industry. The company closed an USD 18.5 million Series B funding round in February 2022, bringing the total funds raised to USD 31.5 million since its founding in 2013. In May 2022, Decisio Health gained a patent (US Patent 11,309,079B2) related to a system, method, and computer program product for providing a patient dashboard system in a hospital setting. The company also rebranded, with the InsightIQ product previously known as DECISIOInsight.
In September 2022, Decisio Health received the Houston Business Journal's Innovation Awards, recognizing its innovative approach to improving patient outcomes and reducing costs through digitized bundles of care.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

In most cases, CDSSs are provided to healthcare providers

Uses digital mediums to generate actionable insights from health data

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Uses IoT to connect databases with medical devices for decision support

Decisio Health

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless